Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105492070> ?p ?o ?g. }
- W2105492070 endingPage "266.e5" @default.
- W2105492070 startingPage "256" @default.
- W2105492070 abstract "The synergistic targeting of DNA damage and DNA repair is a promising strategy for the development of new chemotherapeutic agents for human lung cancer. The DNA interstrand cross-linking agent BO-1509, a derivative of 3a-aza-cyclopenta[α]indene, was synthesized and combined with the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 to treat human lung cancer cells. Our results showed that the BO-1509 and LY294002 combination synergistically killed lung cancer cells in culture and also suppressed the growth of lung cancer xenografts in mice, including those derived from gefitinib-resistant cells. We also found that LY294002 suppressed the induction of several DNA repair proteins by BO-1509 and inhibited the nuclear translocation of Rad51. On the basis of the results of the γH2AX foci formation assays, LY294002 apparently inhibited the repair of DNA damage that was induced by BO-1509. According to the complete blood profile, biochemical enzyme analysis, and histopathologic analysis of major organs, no apparent toxicity was observed in mice treated with BO-1509 alone or in combination with LY294002. Our results suggest that the combination of a DNA cross-linking agent with a PI3K inhibitor is a feasible strategy for the treatment of patients with lung cancer." @default.
- W2105492070 created "2016-06-24" @default.
- W2105492070 creator A5004560801 @default.
- W2105492070 creator A5011888770 @default.
- W2105492070 creator A5012324043 @default.
- W2105492070 creator A5013809644 @default.
- W2105492070 creator A5015242729 @default.
- W2105492070 creator A5031468145 @default.
- W2105492070 creator A5031589359 @default.
- W2105492070 creator A5035281013 @default.
- W2105492070 creator A5069061932 @default.
- W2105492070 date "2014-04-01" @default.
- W2105492070 modified "2023-09-23" @default.
- W2105492070 title "PI3K Inhibition Augments the Therapeutic Efficacy of a 3a-aza-Cyclopenta[α]indene Derivative in Lung Cancer Cells" @default.
- W2105492070 cites W1529396499 @default.
- W2105492070 cites W1534849470 @default.
- W2105492070 cites W1906859011 @default.
- W2105492070 cites W1967630574 @default.
- W2105492070 cites W1971419576 @default.
- W2105492070 cites W1971777367 @default.
- W2105492070 cites W1973615073 @default.
- W2105492070 cites W1976385056 @default.
- W2105492070 cites W1981711832 @default.
- W2105492070 cites W1987345634 @default.
- W2105492070 cites W1988227131 @default.
- W2105492070 cites W1990549862 @default.
- W2105492070 cites W2009445331 @default.
- W2105492070 cites W2009886463 @default.
- W2105492070 cites W2011159055 @default.
- W2105492070 cites W2012169363 @default.
- W2105492070 cites W2012863964 @default.
- W2105492070 cites W2022811243 @default.
- W2105492070 cites W2024509802 @default.
- W2105492070 cites W2027630134 @default.
- W2105492070 cites W2032517155 @default.
- W2105492070 cites W2040932519 @default.
- W2105492070 cites W2041065032 @default.
- W2105492070 cites W2042278676 @default.
- W2105492070 cites W2046848021 @default.
- W2105492070 cites W2047277968 @default.
- W2105492070 cites W2052203436 @default.
- W2105492070 cites W2057115779 @default.
- W2105492070 cites W2059426385 @default.
- W2105492070 cites W2064720809 @default.
- W2105492070 cites W2073234328 @default.
- W2105492070 cites W2074730941 @default.
- W2105492070 cites W2077892030 @default.
- W2105492070 cites W2082382893 @default.
- W2105492070 cites W2087012714 @default.
- W2105492070 cites W2090029719 @default.
- W2105492070 cites W2093212262 @default.
- W2105492070 cites W2094709780 @default.
- W2105492070 cites W2096439168 @default.
- W2105492070 cites W2099334895 @default.
- W2105492070 cites W2103562758 @default.
- W2105492070 cites W2103988494 @default.
- W2105492070 cites W2106787323 @default.
- W2105492070 cites W2107560105 @default.
- W2105492070 cites W2113307269 @default.
- W2105492070 cites W2131659746 @default.
- W2105492070 cites W2132157071 @default.
- W2105492070 cites W2134630203 @default.
- W2105492070 cites W2137124072 @default.
- W2105492070 cites W2137540467 @default.
- W2105492070 cites W2138050607 @default.
- W2105492070 cites W2138297714 @default.
- W2105492070 cites W2139754992 @default.
- W2105492070 cites W2146033265 @default.
- W2105492070 cites W2146625800 @default.
- W2105492070 cites W2150330778 @default.
- W2105492070 cites W2150587707 @default.
- W2105492070 cites W2151606470 @default.
- W2105492070 cites W2152949067 @default.
- W2105492070 cites W2159262037 @default.
- W2105492070 cites W2161598352 @default.
- W2105492070 cites W4252780045 @default.
- W2105492070 cites W4296978003 @default.
- W2105492070 doi "https://doi.org/10.1016/j.tranon.2014.02.012" @default.
- W2105492070 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4101349" @default.
- W2105492070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24913674" @default.
- W2105492070 hasPublicationYear "2014" @default.
- W2105492070 type Work @default.
- W2105492070 sameAs 2105492070 @default.
- W2105492070 citedByCount "1" @default.
- W2105492070 countsByYear W21054920702022 @default.
- W2105492070 crossrefType "journal-article" @default.
- W2105492070 hasAuthorship W2105492070A5004560801 @default.
- W2105492070 hasAuthorship W2105492070A5011888770 @default.
- W2105492070 hasAuthorship W2105492070A5012324043 @default.
- W2105492070 hasAuthorship W2105492070A5013809644 @default.
- W2105492070 hasAuthorship W2105492070A5015242729 @default.
- W2105492070 hasAuthorship W2105492070A5031468145 @default.
- W2105492070 hasAuthorship W2105492070A5031589359 @default.
- W2105492070 hasAuthorship W2105492070A5035281013 @default.
- W2105492070 hasAuthorship W2105492070A5069061932 @default.
- W2105492070 hasBestOaLocation W21054920702 @default.
- W2105492070 hasConcept C134935766 @default.
- W2105492070 hasConcept C142724271 @default.